Stem Cell Therapeutics Corp. Announces Positive Review by Data Safety and Monitoring Board for the Phase IIb Stroke Trial
November 20 2009 - 8:30AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) announced today it has been advised by the Data Safety
Monitoring Board ("DSMB") that a regularly scheduled safety
analysis has been completed and the DSMB has recommended the Phase
IIb stroke trial to continue as per the protocol.
The DSMB is a group of independent clinical experts that review
the ongoing conduct of a clinical trial to ensure continuing
patient safety. The mandate of SCT's DSMB is to provide objective,
independent monitoring of patient safety during the Phase IIb
stroke trial. This review was the first of three formal meetings
scheduled that will occur over the duration of the Phase IIb stroke
trial.
Dr. Alan Moore, President and CEO, commented as follows:
"We are very pleased to receive a positive safety review of the
Phase IIb stroke trial. Review results and enrollment updates will
be announced after each DSMB meeting as progress continues for the
Phase IIb trial. We are also happy to report that 32 patients are
currently enrolled in our Phase IIb stroke study. At this time, we
estimate that Phase IIb patient enrollment will be complete by the
end of Q1 2010 or early in Q2 2010. This will be followed by a
90-day period for completion of patient assessments so we expect
top-line data to be available by the end of Q2 2010 or early in Q3
2010."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Chloe Douglas-Crampton Investor Relations (403)
245-5495 ext. 221 crampton@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024